Prevention of Type 2 Diabetes and Its Complications in Developing Countries: A Review

Lal Rawal1, Robyn J. Tapp2,3, Emily D. Williams1,2, Carina Ka Yee Chan4, Shajahan Yasin4, Brian Oldenburg1
1School of Public Health and Preventive Medicine, Monash University, The Alfred Hospital, Melbourne, Australia
2International Centre for Circulatory Health, NHLI, Imperial College London, London, UK
3Department of Medicine, Monash Medical Centre Southern Clinical School, Monash University, Monash, Australia
4School of Medicine and Health Sciences, Monash University (Sunway Campus), Monash, Malaysia

Tóm tắt

Từ khóa


Tài liệu tham khảo

World Health Organization. Preventing chronic diseases: a vital investment, WHO global report. Geneva: World Health Organization; 2005.

Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: Unwin N et al., editors. Diabetes Atlas. 4th ed. Brussels: International Diabetes Federation; 2009.

World Health Organization. Sixty-first world health assembly, 20 December 2006, a United Nations resolution on diabetes. Geneva: World Health Organization; 2006.

Alberti KGMM, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med. 2007;24:451–63.

International Diabetes Federation, World Health Organization. Diabetes action now, the initiatives of World Health Organization and International Diabetes Federation. Geneva: World Health Organization and International Diabetes Federation; 2004.

World Health Organization, International Diabetes Federation. The western pacific declaration on diabetes. WHO, Western Pacific Regional Office, IDF Western Pacific Region, Secretariat of the Pacific Community and Western Pacific Diabetes Declaration; 2000.

International Diabetes Federation and World Health Organization. The diabetes declaration and strategy for Africa; a call to action and plan of action to prevent and control diabetes and related chronic diseases. International Diabetes Federation, World Health Organization-AFRO and, the African Union; 2006.

Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090–101.

Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D, editor. Diabetes Atlas. 3rd ed. Brussels: International Diabetes Federation; 2006.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. In: Gan D, editor. Diabetes Atlas. 3rd ed. Brussels: International Diabetes Federation; 2006.

Roglic G, Unwin N. Mortality attributable to diabetes: estimates for the year 2010. In: Unwin N et al., editors. Diabetes Atlas. 4th ed. Brussels: International Diabetes Federation; 2009.

Roglic G. Diabetes mortality. In: Gan D, editor. Diabetes Atlas. 3rd ed. Brussels: International Diabetes Federation; 2006.

World Health Organization. Diabetes facts. WHO, fact sheet, November 2008. Switzerland: World Health Organization; 2008.

Mbanya JCN, Motala AA, Sobngwi E, Assah FK, Enoru ST. Diabetes in Sub-Saharan Africa. Lancet. 2010;375:2254–66.

Brown JB, Vistisen D, Sicree R, Shaw J, Nichols G, Zhang P. The economic impacts of diabetes. In: Gan D, editor. Diabetes Atlas. 3rd ed. Brussels: International Diabetes Federation; 2006.

Joslin EP. The prevalence of diabetes mellitus. JAMA. 1921;76:79–84.

World Health Organization Study Group. Prevention of diabetes mellitus—technical report series 844. Geneva: World Health Organization; 1994.

Eriksson KF, Lindgärde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise, the 6-year Malmö feasibility study. Diabetologia. 1991;34:891–8.

Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.

Lindstrom J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, et al. The Finnish diabetes prevention study (DPS), lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003;26:3230–6.

Uusitupa M, Louheranta A, Lindstrom J, Valle T, Sundvall J, Eriksson J, et al. The Finnish diabetes prevention study. Br J Nutr. 2000;83(Suppl):137–42.

Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.

Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007;334:299–302.

Davies MJ, Heller S, Skinner TC, Campbell MJ, Carey ME, Cradock S, et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ. 2008;336:491–5.

Agurs-Collins TD, Kumanyika SK, Ten Have TR, Adams-Campbell LL. A randomized controlled trial of weight reduction and exercise for diabetes management in older African-American subjects. Diabetes Care. 1997;20:1503–11.

Simmons R, Unwin N, Griffin S. International Diabetes Federation: an update of the evidence concerning the prevention of type 2 diabetes. In: Unwin N et al., editors. Diabetes Atlas. 4th ed. Brussels: International Diabetes Federation; 2009.

The World Bank (2009) List of developing countries. July 2008. Available from: http://web.worldbank.org/ . Accessed 21 Sept 2009

Pan X, Li G, Hu Y, Wang J, Yang W, An Z, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and diabetes study. Diabetes Care. 1997;20:537–44.

Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing diabetes prevention study: a 20-year follow-up study. Lancet. 2008;371:1783–9.

Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V, et al. The Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289–97.

Balagopal P, Kamalamma N, Patel TG, Misra R. A community-based diabetes prevention and management education program in a rural village in India. Diabetes Care. 2008;31:1097–104.

World Health Organization. Diabetes mellitus: report of a WHO study group. Technical report series 727. Geneva: World Health Organization; 1985.

World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999.

American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2005;26:33–50.

Sun J, Wang Y, Chen X, Chen Y, Feng Y, Zhang X, et al. An integrated intervention program to control diabetes in overweight Chinese women and men with type 2 diabetes. Asia Pac J Clin Nutr. 2008;17:514–24.

Wattana C, Srisuphan W, Pothiban L, Upchurch SL. Effects of a diabetes self-management program on glycemic control, coronary heart disease risk, and quality of life among Thai patients with type 2 diabetes. Nurs Health Sci. 2007;9:135–41.

Kim HS. A randomized controlled trial of a nurse short-message service by cellular phone for people with diabetes. Int J Nurs Stud. 2007;44:687–92.

Kim HS, Song MS. Technological intervention for obese patients with type 2 diabetes. Appl Nurs Res. 2008;21:84–9.

Ramachandran A, Snehalata C, Yamuna A, Mary S, Ping Z. Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Diabetes Care. 2007;30:2548–52.

Anonymous. Type 2 diabetes—time to change our approach. Lancet 2010;375:2193.

Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hamalainen H, Parikka PI, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.

Samb B, Desai N, Nishtar S, Bekedam H, Wright A, Hsu J, et al. Prevention and management of chronic disease: a litmus test for health-systems strengthening in low-income and middle-income countries. Lancet. 2010;376:1785–97.

McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet. 1991;337:382–6.

The Diabetes Control Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.

UK Prospective Diabetes Study (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.

American Diabetes Association. Standards of medical care in diabetes—2008. Diabetes Care. 2008;31(1):S12–54.

Chaturvedi N. The burden of diabetes and its complications: trends and implications for intervention. Diab Res Clin Pract. 2007;76:S3–12.

Dunstan DW, Mori TA, Puddey IB, Beilin LJ. The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM. A randomized controlled study. Diabetes Care. 1997;20:913–21.

Piette JD, Weinberger M, Kraemer FB, McPhee SJ. Impact of automated calls with nurse follow-up on diabetes treatment outcomes in a department of veterans affairs health care system. Diabetes Care. 2001;24:202–8.

Aubert RE, Herman WH, Waters J, Moore W, Sutton D, Peterson BL, et al. Nurse case management to improve glycemic control in diabetic patients in a health maintenance organization: a randomized controlled trial. Ann Intern Med. 1998;129:605–12.

Meneghini LF, Albisser AM, Goldberg RB, Mintz DH. An electronic case manager for diabetes control. Diabetes Care. 1998;21:591–6.

UK Prospective Diabetes Study (UKPDS). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998;317:703–13.

Waeber B, de la Sierra A, Ruilope LM. The ADVANCE trial: clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus. Am J Cardiovasc Drug. 2009;9:283–91.

Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30:2773–8.

Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.

Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.

So WY, Ozaki R, Chan NN, Tong PCY, Ho CS, Lam CWK, et al. Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients. Hypertension. 2004;44:294–9.

Chogtu B, Singh NP, Chawla S, Gupta U. Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus. Singap Med J. 2009;50:395–9.

Chan JCN, Ko GTC, Leung DHY, Cheung RCK, Cheung MYF, So WY, et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int. 2000;57:590–600.

Chan JCN, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: 1 year analysis. BMJ. 1992;305:981–5.

Diabetes Prevention Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care. 2003;26:36–47.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–7.

Josse RG, Mcguire AJ, Saal GB. A review of the economic evidence for acarbose in the prevention of diabetes and cardiovascular events in individuals with impaired glucose tolerance. Int J Clin Pract. 2006;60:847–55.

Miranda JJ, Kinra S, Casas JP, Davey Smith G, Ebrahim S. Non-communicable diseases in low- and middle-income countries: context, determinants and health policy. Trop Med Int Health. 2008;13:1225–34.

Fisher EB, Earp JA, Maman S, Zolotor A. Cross-cultural and international adaptation of peer support for diabetes management. Fam Pract. 2010;27(Suppl):i6–16.

Lorig K, Ritter PL, Villa FJ, Armas J. Community-based peer-led diabetes self-management: a randomized trial. Diab Educ. 2009;35:641–51.

Lorig K, Ritter PL, Villa F, Piette JD. Spanish diabetes self-management with and without automated telephone reinforcement. Diabetes Care. 2008;31:408–14.

Heisler M. Different models to mobilize peer support to improve diabetes self-management and clinical outcomes: evidence, logistics, evaluation considerations and needs for future research. Fam Pract. 2009;17:1–10.

World Health Organization. Peer support program in diabetes. Report of a WHO consultation, 5–7 November 2007.

Griffiths C, Motlib J, Azad A, Ramsay J, Eldridge S, Feder G, et al. Randomized controlled trial of a lay-led self-management programme for Bangladeshi patients with chronic disease. Br J Gen Pract. 2005;55:831–7.

Colagiuri R, Girgis S, Gomez M, Walker K, Colagiuri S, O’Dea K. National evidence based guideline for the primary prevention of type 2 diabetes. Canberra: Diabetes Australia and the NHMRC; 2009.